Rudbaek, Jonas J. http://orcid.org/0009-0000-1438-5106
Agrawal, Manasi http://orcid.org/0000-0003-4729-1485
Torres, Joana http://orcid.org/0000-0003-2895-5821
Mehandru, Saurabh http://orcid.org/0000-0001-9781-2969
Colombel, Jean-Frederic http://orcid.org/0000-0001-6472-249X
Jess, Tine http://orcid.org/0000-0002-4391-7332
Article History
Accepted: 3 October 2023
First Online: 10 November 2023
Competing interests
: S.M. has received research grants from Genentech and Takeda; payment for lectures from Genentech, Morphic and Taleda; and consulting fees from Arena Pharmaceuticals, Ferring, Morphic and Takeda. J.-F.C. has received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Ferring Pharmaceuticals, Shire and Takeda; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, GlaxoSmithKline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi, Takeda, TiGenix and Vifor; and holds stock options in Intestinal Biotech Development. J.T. has received research grants from AbbVie and Janssen Pharmaceuticals; has received advisory board fees from AbbVie, Janssen Pharmaceuticals, Pfizer and BMS; and has received speaker fees from AbbVie, Janssen Pharmaceuticals and Pfizer. J.J.R., M.A. and T.J. declare no competing interests.